Takeda Pharmaceutical Company Limited 20F 2022 Annual report | TAK Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ACTOVEGIN, Adaptate, AHA, AIPHAGAN, Alagille, Alembic, Alnylam, AML, analyzed, anemia, antiviral, Apr, ARALAST, aspire, atresia, AttenukineTM, Aug, AVISA, awaiting, barrier, Beam, biliary, bio, biodegradable, biographical, BlackRock, blended, Bocconi, booster, broke, Businesswomen, buyback, campaign, Cargo, CDE, CDTO, CEPROTIN, chairperson, Chancery, charitable, Charter, chemotherapy, cidofovir, Classical, CLP, CMML, CMV, CNDAP, coagulant, Coagulation, comfort, Croda, Cure, Dainippon, Darden, Dartmouth, decade, dexlansoprazole, diagnostic, Distinguished, DNA, Dolby, EE, EFPIA, Elizabeth, enantone, endorsed, endpoint, entail, evolution, Evozyne, Excellence, EXKIVITY, familial, family, feet, fell, Fellow, female, fibrostenotic, figure, firmwide, floor, foscarnet, FOSRENOL, Frazier, fSCIg, Gabriele, ganciclovir, gastroesophageal, genotypic, GERD, GHG, GPD, ground, Harvey, healing, heartburn, Hill, HilleVax, HSCT, hypersomnia, ID, ImmTOR, Immusoft, imperative, inbound, infertility, Inpatient, Intermuscular, intrahepatic, Intramuscular, invasion, ISP, IST, ITAC, iTTP, JCR, job, John, Jun, Kellogg, Kennedy, kg, Kimberly, Kobe, ku, Kymera, landfill, Lehman, leiomyomata, LIVETENCITY, LIVTENCITY, Lupin, LUPRON, Luxna, mantle, Maraganore, maralixibat, MCL, Mesothelin, MIB, Milan, Mirum, mobocertinib, modakafusp, movement, Mudd, myelomonocytic, needle, Northwestern, nuvaxovid, Oak, OBU, occupancy, OCE, OECD, Omicron, onset, operationalized, Oxford, pabinafusp, PANTHER, particulate, PAS, perioperative, pevonedistat, piggyBac, pillar, PIPL, platinum, Polytechnic, ponatinib, Poseida, pp, PreviPharma, progranulin, prompted, PROTHROMPLEX, PSU, puberty, rapid, rebound, redefine, Reed, Regensburg, Ricci, roll, Rome, RSU, Russian, Sandoz, Sanitary, satisfaction, scrutiny, SE, Selecta, shipping, Sigmapharm, signal, smart, societal, Sosei, spearheaded, spikevax, square, star, survival, symptomatic, synthesizing, TAC, tau, tenure, Tor, transferrin, Trieste, TV, unclarity, undelivered, undistributed, Unfit, unpunctured, unremitted, val, valganciclovir, variant, VBU, VECTIBIX, venetoclax, Vergata, Virginia, Waring, weighing, Wellesley, withdrawn, xeno, Yodogawa

Removed: abandon, acellular, activating, admitted, aerospace, Akzo, Alogliptin, Amato, amyotrophic, artery, Asahi, Assistant, Asthma, attenukine, Automobile, BacTrap, bid, Biodefense, bioterrorism, calcium, Centre, CEPI, Chase, checkpoint, claiming, Coalition, conformed, conjunction, COO, coronary, correlate, count, DAAO, de, deleveraging, depression, discontinuance, Dopamine, DOYUKAI, Dresser, eASC, EBARA, effort, Electron, EM, emphasizing, employer, Epidemic, ethical, existed, explore, feasibility, Fellowship, forma, Francisco, Fred, gained, GAVI, GM, grossed, Guangdong, harbor, headed, hearing, Hemoshear, hifibio, HPT, Huntington, Hutchinson, IAVI, IGF, incidental, INCJ, indemnification, indemnify, indenture, interacting, Interbrew, Inviragen, ITP, Jeffrey, JPMorgan, Kajima, Kawasaki, Keidanren, KEIZAI, Komatsu, labor, LATAM, leased, LigoCyte, longstanding, Louisiana, LPC, lymphocytic, Mallinckrodt, Marek, Markman, Masahiro, mature, Medipal, Melinda, Mersana, micro, Mississippi, Mizuho, Modell, moved, MUFG, Multilab, NEDD, negotiating, NEXON, NIDEC, Nihon, Nobel, Nomura, noncorporate, Novamed, Novimmune, officially, Opex, Organon, originating, outlined, Ovarian, oxidase, pace, pan, pattern, PENTASA, pill, pioglitazone, platelet, player, polio, positioning, PPTA, promising, Protease, provisional, PTH, pulmonary, purport, PvP, Rajeev, ran, reacquired, reacquisition, realignment, Redirected, remained, remove, Rent, repaid, resetting, retrospective, returning, Ricardo, seasoned, Shanghai, shared, side, Sony, SPRInT, sublease, Sunstar, Tabular, takeover, Techpool, tendered, trained, unfiled, user, velaglucerase, Venkayya, Virology, whilst, White, Yakuhin, Yasuhiko

Takeda Pharmaceutical Company Limited (TAK) 20-F2022 FY Annual report (foreign)

Content analysis